Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2020-12-08 04:17:002021-03-08 18:11:32Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board
Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515. If granted, […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2020-11-02 04:40:002021-03-08 21:43:36Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041
Los Angeles, January 31, 2019 /PRNewswire/ — Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, announced the nomination and acceptance of Timothy Donahue to Trethera’s Board of Directors by unanimous vote of the Board. “I am delighted to have Dr. Donahue join the […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2019-01-31 15:31:032019-01-31 15:31:17Trethera Corporation announces appointment of Timothy “Tim” Donahue, M.D. to the Board of Directors
Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board
/in News /by TretheraLos Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]
Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041
/in News /by TretheraLos Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515. If granted, […]
Trethera Corporation announces appointment of Timothy “Tim” Donahue, M.D. to the Board of Directors
/in Events, News /by TretheraLos Angeles, January 31, 2019 /PRNewswire/ — Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, announced the nomination and acceptance of Timothy Donahue to Trethera’s Board of Directors by unanimous vote of the Board. “I am delighted to have Dr. Donahue join the […]